Aleph, or ALEPH-1, also known as DOT or para-DOT or as 4-methylthio-2,5-dimethoxyamphetamine, is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is one of the Aleph series of compounds.
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists Aleph's dose range as 5 to 10mg orally and its duration as 6 to 8hours. The effects of Aleph have been reported to include simple tasks feeling "alien", intense intellectual stimulation, impairment, a sensation of pleasant physical warmth, and an afterglow including feelings of empathy for everything.
Aleph is known to be a partial agonist of the serotonin 5-HT<sub>2A</sub> receptor ( = 10âÂÂ66nM; = 114âÂÂ191%).
It has weak MAO-A inhibitory activity with an of 5.2üM. For comparison, amphetamine has an IC<sub>50</sub> of 11üM and 4-methylthioamphetamine (4-MTA) has a value of 0.2üM.
The chemical synthesis of Aleph has been described.
Derivatives of Aleph include Aleph-2, Aleph-4, Aleph-6, and Aleph-7. The Aleph series of compounds are the DOx or amphetamine analogues of 2C-T, 2C-T-2, 2C-T-4, 2C-T-6, and 2C-T-7, respectively.
Aleph was first tested by Alexander Shulgin in 1975. It was first described in the scientific literature by Shulgin and David E. Nichols in 1976. Its properties and effects in humans were described by them in 1978. Subsequently, the drug was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
Aleph was named by Alexander Shulgin, who named it after the first letter of the Hebrew alphabet. Another earlier name of the drug is para-DOT.
Aleph is a controlled substance in Canada under phenethylamine blanket-ban language.
In the United States, Aleph is a Schedule 1 controlled substance as a positional isomer of 2C-T-4 and 2C-T-7.